This week, at the J.P. Morgan Healthcare Conference and the Biotech Showcase, discussions underscored the growing focus on innovation in cell and gene therapies. Against this backdrop, the US Food and Drug Administration (FDA) reinforced its ongoing commitment to transformative […]
Streamlining rare disease drug approvals Read More »
As companies across the pharma and biotech sectors gathered at the annual JPM Healthcare Conference 2025, held from 13 January to 16 January in San Francisco, company presentations gave a view of the factors driving their growth in this market.
Interleukin inhibitors remain a strong growth driver in dermatology Read More »
Approaching his 200th day as the new Chief Executive Officer of Lonza, Wolfgang Wienand discussed the company’s plans to exit the Capsules and Health Ingredients (CHI) business and concentrate on core contract manufacturing at the 43rd JP Morgan Annual Healthcare
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy Read More »
The first day of the JP Morgan Healthcare Conference held in San Francisco, California from 13 January to 15 January 2025 began with Johnson & Johnson, Eli Lilly and GSK announcing mergers and acquisitions (M&A) deals each exceeding $1 billion,
Is biopharma M&A poised for a rebound? Read More »
The chronic obstructive pulmonary disease (COPD) market continues its trajectory of rapid growth, bolstered by significant advancements in biologics and sustained investments by major pharmaceutical players. AstraZeneca’s recent presentation at the JPM Healthcare Conference 2025 highlighted the company’s commitment to
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth Read More »
WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than-expected revenue projections. On 15 January at the 43rd JP Morgan Healthcare Conference, WuXi AppTec Co-CEO Minzhang
Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is characterised by progressive muscle degeneration and weakness, and is caused by mutations in the dystrophin gene. Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance Read More »
During its presentation at the JP Morgan Healthcare Conference 2025, Johnson and Johnson (J&J) suggested it would undertake an aggressive strategic approach in the immunology space for the coming year. While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated
Protection of Stelara may indicate J&J’s immunology strategy Read More »
Thermo Fisher Scientific is looking to build upon its strong momentum from last year as it enters 2025. The company plans to deploy its proven growth strategy and continue to drive share gain, execute mergers and acquisitions (M&A) and return
JP Morgan 2025: Thermo Fisher rides momentum to project strong growth in 2025 Read More »
On 13 January 2024, Johnson & Johnson (J&J) announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specialising in developing treatments targeting complex psychiatric and neurological disorders. The deal is valued at $14.6 billion and is the biggest biotech mergers
J&J to leverage Intra-Cellular Therapies’ neurology portfolio Read More »
